

**UP AND UP NON DROWSY ALLERGY RELIEF- fexofenadine
hydrochloride tablet, coated
Target Corporation**

Target Corporation Non-Drowsy Allergy Relief Drug Facts

Active ingredient (in each tablet)

Fexofenadine HCl 180 mg

Purpose

Antihistamine

Uses

temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:

- runny nose
- itchy, watery eyes
- sneezing
- itching of the nose or throat

Warnings

Do not use

if you have ever had an allergic reaction to this product or any of its ingredients.

Ask a doctor before use if you have

kidney disease. Your doctor should determine if you need a different dose.

When using this product

- do not take more than directed
- do not take at the same time as aluminum or magnesium antacids
- do not take with fruit juices (see Directions)

Stop use and ask a doctor if

an allergic reaction to this product occurs. Seek medical help right away.

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

Directions

adults and children 12 years of age and over	take one 180 mg tablet with water once a day; do not take more than 1 tablet in 24 hours
children under 12 years of age	do not use
adults 65 years of age and older	ask a doctor
consumers with kidney disease	ask a doctor

Other information

- do not use if printed foil under cap is broken or missing
- store between 20°-25°C (68°-77°F)
- protect from excessive moisture
- this product meets the requirements of USP *Dissolution Test 2*

Inactive ingredients

colloidal silicone dioxide, croscarmellose sodium, D&C red #27 aluminum lake, FD&C blue #1 aluminum lake, gelatin, glycerin, lactose monohydrate, lecithin, magnesium stearate, maltitol solution, medium chain triglycerides, microcrystalline cellulose, pharmaceutical ink, polyethylene glycol, polyvinyl alcohol, pregelatinized starch, stearic acid, talc, titanium dioxide

Questions or comments?

1-888-547-7400

Package/Label Principal Display Panel

Compare to active ingredient in Allegra® Allergy

Non-Drowsy Allergy Relief

Fexofenadine Hydrochloride Tablets 180 mg / Antihistamine

Indoor and outdoor allergy relief of sneezing; runny nose; itchy, watery eyes; itchy nose or throat

24 Hour

GCP

up&up™

60 GELTABS*, 180 mg EACH

*GELATIN COATED TABLETS

Actual Size 60 Geltabs*



UP AND UP NON DROWSY ALLERGY RELIEF

fexofenadine hydrochloride tablet, coated

Product Information

Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:82442-300	
Route of Administration	ORAL			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
FEXOFENADINE HYDROCHLORIDE (UNII: 2S068B75ZU) (FEXOFENADINE - UNII:E6582LOH6V)		FEXOFENADINE HYDROCHLORIDE	180 mg	
Inactive Ingredients				
Ingredient Name			Strength	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)				
CROSCARMELOSE SODIUM (UNII: M28OL1HH48)				
D&C RED NO. 27 (UNII: 2LRS185U6K)				
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)				
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)				
GLYCERIN (UNII: PDC6A3C0OX)				
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)				
MAGNESIUM STEARATE (UNII: 70097M6I30)				
MALTITOL (UNII: D65DG142WK)				
MEDIUM-CHAIN TRIGLYCERIDES (UNII: C9H2L21V7U)				
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)				
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)				
POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)				
STEARIC ACID (UNII: 4ELV7Z65AP)				
TALC (UNII: 7SEV7J4R1U)				
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)				
Product Characteristics				
Color	WHITE, PURPLE	Score	no score	
Shape	OVAL	Size	18mm	
Flavor		Imprint Code	GCP	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:82442-300-72	1 in 1 CARTON	03/04/2024	
1		60 in 1 BOTTLE; Type 0: Not a Combination Product		
Marketing Information				
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date

ANDA	ANDA212971	03/04/2024	
------	------------	------------	--

Labeler - Target Corporation (006961700)

Revised: 3/2024

Target Corporation